BioCentury
ARTICLE | Finance

Targeting translation

Novel biology, chemistry behind big A round for oncogene play Effector

May 27, 2013 7:00 AM UTC

Effector Therapeutics Inc. recorded the second-largest series A round thus far this year, driven by novel biology and founders and management with a track record of exits.

The company raised $45 million in a tranched round co-led by U.S. Venture Partners; Abingworth; Novartis Venture Funds; and SR One. Astellas Venture Management; Osage University Partners; and Mission Bay Capital also participated. The tranches are not disclosed...